Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | - | - | −62.5% |
| Operating Income | −¥0.96B | −¥0.82B | −17.3% |
| Ordinary Income | −¥0.95B | −¥0.81B | −17.2% |
| Net Income | −¥0.96B | −¥0.82B | −17.2% |
| ROE (Annualized) | −114.6% | −117.6% | - |
Executive Summary
As a research and development-focused biotechnology company, the Company’s operating loss widened year on year for the current period, and its cost-front-loaded structure remains in place. The operating loss was ¥0.96B (¥0.82B in the same period of the previous year), the ordinary loss was ¥0.95B (¥0.81B in the previous year), and net income was a loss of ¥0.96B (a loss of ¥0.82B in the previous year). Revenue was virtually unrecognized, declining 62.5% year on year. The primary factor behind the widening loss was a 17.3% year-on-year increase in SG&A expenses, with upfront R&D and organizational operating costs determining profitability.
Factors Affecting Results
【Revenue】Revenue was virtually unrecognized, declining 62.5% year on year. As a research and development-focused company, performance evaluation at this stage centers not on product sales but on pipeline progress and the realization of partnership revenue.
【Profit and Loss】SG&A expenses were ¥0.96B, an increase of 17.3% from ¥0.82B in the same period of the previous year, and the operating loss widened to ¥0.96B (¥0.82B in the previous year). Non-operating income and expenses resulted in a net gain of only ¥0.004B, an amount insufficient to offset the operating loss. The Company recorded an impairment loss of ¥0.001B as an extraordinary loss, but its impact was limited. The ordinary loss was ¥0.95B and net income was a loss of ¥0.96B, broadly in line with the operating loss, with no significant divergence caused by temporary factors. With expenses increasing despite virtually no revenue, the Company is in a state of declining revenue and widening losses.
Key Financial Indicators
【Profitability】Because virtually no revenue was recognized, profit margin analysis relative to revenue is not applicable. ROE (annualized) was -114.6% and the equity ratio was 81.4%; while return on capital was significantly negative, the financial foundation remained conservative.【Cash Quality】Cash and deposits were ¥0.94B, representing 69.2% of total assets. Despite recording a net loss, the cash balance increased year on year due to capital raising.【Investment Efficiency】Fixed assets were small at ¥0.05B, with most invested capital held as cash. The results of investments in the pipeline will be the focus for future efficiency improvements.【Financial Soundness】Current assets of ¥1.31B compared with current liabilities of ¥0.19B resulted in a high current ratio. Fixed liabilities were also limited at ¥0.07B, indicating a low level of debt and limited short-term liquidity risk. However, retained earnings deteriorated to -¥4.76B from -¥3.80B in the same period of the previous year, reflecting continued capital consumption from recurring losses.
Cash Flow Analysis
Cash and deposits increased by ¥0.13B to ¥0.94B from ¥0.81B in the same period of the previous year. However, as the Company recorded a net loss of ¥0.96B during this period, the increase in cash appears to have resulted from capital raising rather than profit generation. Capital stock and capital surplus both increased year on year, indicating that external funding supported the financial foundation and liquidity. Cash accounted for 69.2% of total assets and provided a buffer for near-term operating funding. However, given the pace of ongoing losses, future funding activity and the execution of R&D expenditures will be important monitoring items from a liquidity perspective.
Quality of Earnings
The current-period loss was primarily attributable to the recurring cost structure, including increased SG&A expenses. Extraordinary losses consisted of a relatively small impairment loss of ¥0.001B, and the impact of temporary factors was limited. Non-operating income and expenses were broadly balanced, comprising non-operating income of ¥0.01B and non-operating expenses of ¥0.01B (including a foreign exchange loss of ¥0.01B). Accordingly, the ordinary loss and operating loss were broadly at the same level. Because expenses continue to accumulate despite virtually no revenue, it is not yet meaningful to discuss earnings quality from an accrual perspective. Since expenses involving cash outflows are directly recognized as losses, the divergence between the accounting presentation and underlying reality is considered limited.
Earnings Forecast and Guidance
The full-year company forecast consists of an operating loss of ¥1.18B, an ordinary loss of ¥1.16B, and net income of a loss of ¥1.17B. The Q3 cumulative operating loss of ¥0.96B represents 80.9% progress toward the full-year forecast, exceeding the 75% benchmark for evenly distributed quarterly progress by 5.9pt. The net loss also represents 81.9% progress toward the full-year forecast, with losses being recorded at a pace exceeding standard progress. The operating loss permitted for the remaining quarter is approximately ¥0.23B, below the average quarterly loss for the most recent three quarters. Accordingly, achieving the full-year forecast will require cost controls in Q4.
Shareholder Returns
The Q2 dividend was ¥0 per share, and the Company continues to pay no dividends. The full-year dividend forecast is also ¥0, with no revision to the dividend forecast during the current quarter. Given the recorded net loss and retained earnings of -¥4.76B, the payout ratio is effectively 0%, and capital allocation to R&D and working capital is currently being prioritized.
Risk Factors
-
Capital consumption risk from continued losses: The current-period net loss was ¥0.96B, and retained earnings deteriorated to -¥4.76B, meaning that additional funding will be required to continue R&D.
-
Capital raising and dilution risk: The total of capital stock and capital surplus increased year on year, and the Company continues to rely on equity financing for loss coverage and development funding.
-
Risk of exceeding the full-year loss forecast: Progress toward the full-year operating loss forecast was 80.9%, exceeding the Q3 standard of 75%, requiring cost controls in Q4.
Industry Benchmark (For Reference; Compiled by the Company)
Industry Benchmark (pharma)
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (Year on Year) | −62.5% | -9.0% (-20.4%–11.2%) | −53.5pt |
The Company’s revenue growth rate was significantly below the industry median, primarily because product revenue was virtually unrecognized as the Company remains in the R&D stage.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
The operating loss widened by 17.3% year on year, with increased expenses serving as the primary short-term driver of performance. Meanwhile, the current ratio remained high, and short-term financial stability was maintained due to cash of ¥0.94B and low debt levels.
-
The increase in net assets was not attributable to profit generation but primarily to capital raising through increases in capital stock and capital surplus. Retained earnings have deteriorated due to continued losses, and future funding activity may become a turning point in the financial structure.
-
Progress toward the full-year operating loss forecast was 80.9%, exceeding the Q3 standard, making Q4 expenditure execution the key factor in achieving the full-year forecast.
Theoretical Share Price (Reference Value)
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥0 |
| base (base case) | ¥0 |
| bull (bullish) | ¥0 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥10 |
| Adjusted Forecast EPS | -¥12.9 |
| Cost of Equity r | 10.87% (10-year Japanese government bond 2.87% + equity risk premium 6.00% + size premium 2.00%) |
| Residual Income Persistence Coefficient ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 30.0% |
| Forecast EPS Confidence Adjustment | ×1.000 (based on the industry’s historical guidance achievement rate) |
Sensitivity: -¥3 to -¥3 for a ±1% change in the cost of equity, and -¥3 to -¥3 for a ±0.1 change in ω.
Notes:
- As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the quarter-end are used (there is a time lag relative to the full-year forecast).
- As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.
(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-08 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee the future share price.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional advisor as necessary.
---End of Report---